On 10 July 2007, the Dublin High Court held that Ranbaxy’s product infringes the Pfizer Base patent.
Same result, different country (see the scorecard on this site for details). [Note, though that based on an appellate decision in late May, Ranbaxy can now launch in Norway.]
Appeals in this dispute are pending in a few jurisdictions at the moment.
It will be interesting to see who will launch next and when (of the very many other companies preparing to launch atorvastatin).